Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientific Officer Daniel Lorrain

Benzinga · 3d ago

Contineum has streamlined its discovery programs to focus on drug candidates for the treatment of inflammatory and fibrotic diseases. These actions have resulted in a limited workforce reduction for the Company’s research team, including Contineum’s Chief Scientific Officer, Daniel Lorrain, Ph.D.